Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
$2.59
-2.6%
$2.59
$1.20
$6.75
$151.26M2.87893,995 shs708,420 shs
CEL-SCI Co. stock logo
CVM
CEL-SCI
$9.45
+15.5%
$3.59
$1.98
$39.30
$50.28M0.3380,418 shs521,184 shs
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
$2.62
+30.3%
$2.13
$0.60
$3.44
$163.82M1.38329,517 shs44.48 million shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$12.58
+0.2%
$12.82
$7.09
$27.38
$157.98M0.45134,697 shs64,103 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
-2.63%-12.79%-0.38%+45.51%-57.47%
CEL-SCI Co. stock logo
CVM
CEL-SCI
+15.53%+15.24%+275.00%+25.50%-72.25%
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
+30.35%+24.17%+14.41%+176.43%+88.49%
Lifevantage Corporation stock logo
LFVN
Lifevantage
+0.24%-8.24%-6.12%+5.63%+53.79%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
2.3023 of 5 stars
3.51.00.00.03.11.70.6
CEL-SCI Co. stock logo
CVM
CEL-SCI
1.2111 of 5 stars
0.02.00.00.04.31.70.6
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
2.5118 of 5 stars
3.75.00.00.00.61.70.0
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.8043 of 5 stars
3.50.01.72.71.12.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
3.00
Buy$12.80394.21% Upside
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.00
N/AN/AN/A
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
3.33
Buy$6.00129.01% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50142.45% Upside

Current Analyst Ratings Breakdown

Latest CVM, LFVN, IMAB, and BDTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
7/9/2025
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00
7/1/2025
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform$11.00
6/27/2025
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$4.00 ➝ $5.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
N/AN/AN/AN/A$1.47 per shareN/A
CEL-SCI Co. stock logo
CVM
CEL-SCI
N/AN/AN/AN/A$0.15 per shareN/A
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
$3.89M54.89N/AN/A$2.47 per share1.06
Lifevantage Corporation stock logo
LFVN
Lifevantage
$200.16M0.79$0.88 per share14.23$2.05 per share6.14
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
-$69.68M$0.0643.17N/AN/AN/A4.70%3.47%8/5/2025 (Estimated)
CEL-SCI Co. stock logo
CVM
CEL-SCI
-$26.92M-$12.61N/AN/AN/AN/A-238.05%-104.65%N/A
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
-$22.23MN/A0.00N/AN/AN/A-19.81%-18.63%8/27/2025 (Estimated)
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6918.23N/A4.12%34.67%15.24%8/27/2025 (Estimated)

Latest CVM, LFVN, IMAB, and BDTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/27/2025Q2 2025
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
-$0.10N/AN/AN/AN/AN/A
8/27/2025Q4 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.17N/AN/AN/A$57.93 millionN/A
8/5/2025Q2 2025
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
-$0.26N/AN/AN/AN/AN/A
5/6/2025Q3 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
N/AN/AN/AN/AN/A
CEL-SCI Co. stock logo
CVM
CEL-SCI
N/AN/AN/AN/AN/A
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.43%N/A26.09%3 Years
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
N/A
9.24
9.24
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.66
1.07
1.09
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/A
22.35
22.35
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98

Institutional Ownership

CompanyInstitutional Ownership
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
95.47%
CEL-SCI Co. stock logo
CVM
CEL-SCI
12.08%
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
38.38%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%

Insider Ownership

CompanyInsider Ownership
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
5.97%
CEL-SCI Co. stock logo
CVM
CEL-SCI
9.93%
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
22.10%
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
9056.86 million53.47 millionOptionable
CEL-SCI Co. stock logo
CVM
CEL-SCI
435.32 million64.67 millionOptionable
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
38081.50 million63.49 millionOptionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable

Recent News About These Companies

LifeVantage To Open Iceland Market

New MarketBeat Followers Over Time

Media Sentiment Over Time

Black Diamond Therapeutics stock logo

Black Diamond Therapeutics NASDAQ:BDTX

$2.59 -0.07 (-2.63%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$2.62 +0.03 (+1.16%)
As of 08/1/2025 07:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

CEL-SCI stock logo

CEL-SCI NYSE:CVM

$9.45 +1.27 (+15.53%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$9.29 -0.16 (-1.69%)
As of 08/1/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

I-Mab stock logo

I-Mab NASDAQ:IMAB

$2.62 +0.61 (+30.35%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$2.54 -0.08 (-2.86%)
As of 08/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$12.58 +0.03 (+0.24%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$12.57 -0.01 (-0.08%)
As of 08/1/2025 05:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.